Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000950170-25-090997
Filing Date
2025-06-27
Accepted
2025-06-27 17:00:35
Documents
1
Period of Report
2025-06-25

Document Format Files

Seq Description Document Type Size
1 4 ownership.html 4  
1 4 ownership.xml 4 16649
  Complete submission text file 0000950170-25-090997.txt   18216
Mailing Address 7TH FLOOR, 50 BROADWAY LONDON UNITED KINGDOM United Kingdom SW1H 0DB
Business Address 7TH FLOOR, 50 BROADWAY LONDON UNITED KINGDOM United Kingdom SW1H 0DB 441-295-5950
Roivant Sciences Ltd. (Issuer) CIK: 0001635088 (see all company filings)

EIN.: 981173944 | State of Incorp.: D0 | Fiscal Year End: 0331
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 15 CHESTNUT HILL LANE BRIARCLIFF MANOR NY 10510
Business Address
Gold Daniel Allen (Reporting) CIK: 0001832142 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-40782 | Film No.: 251087451